TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $122.70.

Several research analysts have issued reports on TMDX shares. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, February 5th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. TD Cowen reduced their price objective on TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research note on Monday, November 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday. Finally, Robert W. Baird dropped their target price on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Braidwell LP purchased a new stake in shares of TransMedics Group during the 4th quarter worth $57,493,000. Norges Bank acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $22,861,000. Mackenzie Financial Corp boosted its holdings in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after buying an additional 349,403 shares in the last quarter. Dimensional Fund Advisors LP grew its position in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the period. Finally, Emerald Advisers LLC increased its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after buying an additional 220,804 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Remove Ads

TransMedics Group Stock Performance

Shares of TMDX traded down $0.46 during mid-day trading on Friday, reaching $67.19. 499,575 shares of the company's stock were exchanged, compared to its average volume of 1,979,848. The business's fifty day simple moving average is $68.55 and its 200-day simple moving average is $95.67. The stock has a market capitalization of $2.26 billion, a PE ratio of 71.93 and a beta of 2.12. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.